Net service revenue increased $18.6 million to $380.2 million compared to $361.6 million in 2016.
BATON ROUGE, La., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED) today reported its financial results for the three and nine-month periods ended September 30, 2017.
Three Month Periods Ended September 30, 2017 and 2016
- Net service revenue increased $18.6 million to $380.2 million compared to $361.6 million in 2016.
- Net income attributable to Amedisys, Inc. of $14.6 million compared to $11.4 million in 2016.
- Net income attributable to Amedisys, Inc. per diluted share of $0.42 compared to $0.34 in 2016.
Adjusted Quarterly Results*
- Adjusted EBITDA of $36.9 million compared to $25.6 million in 2016.
- Adjusted net service revenue of $386.7 million compared to $361.6 million in 2016.
- Adjusted net income attributable to Amedisys, Inc. of $19.2 million compared to $12.1 million in 2016.
- Adjusted net income attributable to Amedisys, Inc. per diluted share of $0.56 compared to $0.36 in 2016.
Nine Month Periods Ended September 30, 2017 and 2016
- Net service revenue increased $58.3 million to $1,129.4 million compared to $1,071.1 million in 2016.
- Net income attributable to Amedisys, Inc. of $34.1 million compared to $28.3 million in 2016.
- Net income attributable to Amedisys, Inc. per diluted share of $1.00 compared to $0.84 in 2016.
Adjusted Year to Date Results*
- Adjusted EBITDA of $105.0 million compared to $79.4 million in 2016.
- Adjusted net service revenue of $1,135.9 million compared to $1,072.1 million in 2016.
- Adjusted net income attributable to Amedisys, Inc. of $56.5 million compared to $37.2 million in 2016.
- Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.65 compared to $1.10 in 2016.
* See the Reconciliation of Non-GAAP Financial Measures to GAAP Measures table for the definition and reconciliations of non-GAAP financial measures to GAAP measures.
Paul B. Kusserow, President and Chief Executive Officer stated, “I am proud of our third quarter results and the strong execution of our team. We are pleased with the growth trends we are seeing in home health, after experiencing some obstacles in the last few quarters. Our strategies around home health business development hiring, retention and training are delivering the desired results, and now we must continue that momentum. Our hospice segment continues its stellar performance, with 18% revenue growth compared to the third quarter of 2016. Our personal care segment has built out an impressive platform for growth in under two years and has integrated tuck-in acquisitions to fill out its footprint in Massachusetts. Most importantly, our clinical and outcomes metrics continue to improve as we pursue the goal of clinical distinction for our patients, referral sources and payors. On the regulatory side, we are pleased with the CMS decision not to finalize the home health groupings model. While we are supportive of payment reform in home health, we must ensure that any reform is designed such that patient access to home health services is not negatively impacted. Finally, thanks to our team of over 17,000 employees for continuing to provide excellent care to our patients.”
We urge caution in considering the current trends disclosed in this press release. The home health and hospice industry is highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com.
Earnings Call and Webcast Information
Amedisys will host a conference call on Wednesday, November 8, 2017, at 11:00 a.m. ET to discuss its third quarter results. To participate on the conference call, please call before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through December 8, 2017 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13672018.
A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.
Non-GAAP Financial Measures
This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (4) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.
Additional information
Amedisys, Inc. (the “Company”) is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 17,000 employees, in 425 care centers in 34 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 385,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.
We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.
Forward-Looking Statements
When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, competition in the healthcare industry, our ability to integrate our personal care segment into our business efficiently, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, our ability to integrate, manage and keep our information systems secure, our ability to comply with requirements stipulated in our corporate integrity agreement and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
| Contact: | Investor Contact: | Media Contact: | |||
| Amedisys, Inc. | Amedisys, Inc. | ||||
| David Castille | Kendra Kimmons | ||||
| Managing Director, Treasury/Finance | Vice President, Marketing & Communications | ||||
| (855) 259-2046 | (225) 299-3720 | ||||
| IR@amedisys.com | kendra.kimmons@amedisys.com |
| AMEDISYS, INC. AND SUBSIDIARIES | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||||||
| (Amounts in thousands, except per share data) | |||||||||||||||
| (Unaudited) | |||||||||||||||
| For the Three Month Period Ended September 30, | For the Nine Month Period Ended September 30, | ||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||
| Net service revenue | $ | 380,163 | $ | 361,595 | $ | 1,129,442 | $ | 1,071,158 | |||||||
| Cost of service, excluding depreciation and amortization | 226,642 | 212,124 | 662,192 | 620,466 | |||||||||||
| General and administrative expenses: | |||||||||||||||
| Salaries and benefits | 77,130 | 77,019 | 226,532 | 231,079 | |||||||||||
| Non-cash compensation | 3,558 | 4,750 | 11,788 | 12,556 | |||||||||||
| Other | 38,189 | 42,658 | 120,223 | 134,951 | |||||||||||
| Provision for doubtful accounts | 7,086 | 5,471 | 18,078 | 13,664 | |||||||||||
| Depreciation and amortization | 4,185 | 5,214 | 13,139 | 14,662 | |||||||||||
| Securities Class Action Lawsuit settlement, net | — | — | 28,712 | — | |||||||||||
| Operating expenses | 356,790 | 347,236 | 1,080,664 | 1,027,378 | |||||||||||
| Operating income | 23,373 | 14,359 | 48,778 | 43,780 | |||||||||||
| Other income (expense): | |||||||||||||||
| Interest income | 44 | 14 | 104 | 45 | |||||||||||
| Interest expense | (1,335 | ) | (1,136 | ) | (3,600 | ) | (3,551 | ) | |||||||
| Equity in earnings from equity method investments | 900 | 3,244 | 3,149 | 3,602 | |||||||||||
| Miscellaneous, net | 1,043 | 1,713 | 3,282 | 3,106 | |||||||||||
| Total other income, net | 652 | 3,835 | 2,935 | 3,202 | |||||||||||
| Income before income taxes | 24,025 | 18,194 | 51,713 | 46,982 | |||||||||||
| Income tax expense | (9,364 | ) | (6,693 | ) | (17,324 | ) | (18,323 | ) | |||||||
| Net income | 14,661 | 11,501 | 34,389 | 28,659 | |||||||||||
| Net income attributable to noncontrolling interests | (103 | ) | (66 | ) | (240 | ) | (315 | ) | |||||||
| Net income attributable to Amedisys, Inc. | $ | 14,558 | $ | 11,435 | $ | 34,149 | $ | 28,344 | |||||||
| Basic earnings per common share: | |||||||||||||||
| Net income attributable to Amedisys, Inc. common stockholders | $ | 0.43 | $ | 0.34 | $ | 1.02 | $ | 0.86 | |||||||
| Weighted average shares outstanding | 33,838 | 33,309 | 33,640 | 33,142 | |||||||||||
| Diluted earnings per common share: | |||||||||||||||
| Net income attributable to Amedisys, Inc. common stockholders | $ | 0.42 | $ | 0.34 | $ | 1.00 | $ | 0.84 | |||||||
| Weighted average shares outstanding | 34,363 | 33,823 | 34,255 | 33,699 | |||||||||||
| AMEDISYS, INC. AND SUBSIDIARIES | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEET | |||||||
| (Amounts in thousands, except share data) | |||||||
| September 30, 2017 | |||||||
| (Unaudited) | December 31, 2016 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 66,114 | $ | 30,197 | |||
| Patient accounts receivable, net of allowance for doubtful accounts of $19,933 and $17,716 | 177,402 | 166,056 | |||||
| Prepaid expenses | 9,770 | 7,397 | |||||
| Other current assets | 14,904 | 11,260 | |||||
| Total current assets | 268,190 | 214,910 | |||||
| Property and equipment, net of accumulated depreciation of $148,301 and $138,650 | 32,695 | 36,999 | |||||
| Goodwill | 313,663 | 288,957 | |||||
| Intangible assets, net of accumulated amortization of $29,932 and $27,864 | 44,845 | 46,755 | |||||
| Deferred income taxes | 91,160 | 107,940 | |||||
| Other assets, net | 48,976 | 38,468 | |||||
| Total assets | $ | 799,529 | $ | 734,029 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 22,815 | $ | 30,358 | |||
| Payroll and employee benefits | 86,139 | 82,480 | |||||
| Accrued expenses | 83,516 | 63,290 | |||||
| Current portion of long-term obligations | 9,387 | 5,220 | |||||
| Total current liabilities | 201,857 | 181,348 | |||||
| Long-term obligations, less current portion | 80,523 | 87,809 | |||||
| Other long-term obligations | 3,930 | 3,730 | |||||
| Total liabilities . | 286,310 | 272,887 | |||||
| Equity: | |||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding | — | — | |||||
| Common stock, $0.001 par value, 60,000,000 shares authorized; 35,687,068 and 35,253,577 shares issued; and 33,913,558 and 33,597,215 shares outstanding | 36 | 35 | |||||
| Additional paid-in capital | 561,380 | 537,472 | |||||
| Treasury stock at cost, 1,773,510 and 1,656,362 shares of common stock | (53,228 | ) | (46,774 | ) | |||
| Accumulated other comprehensive income | 15 | 15 | |||||
| Retained earnings (deficit) | 4,053 | (30,545 | ) | ||||
| Total Amedisys, Inc. stockholders’ equity | 512,256 | 460,203 | |||||
| Noncontrolling interests | 963 | 939 | |||||
| Total equity | 513,219 | 461,142 | |||||
| Total liabilities and equity | $ | 799,529 | $ | 734,029 | |||
| AMEDISYS, INC. AND SUBSIDIARIES | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING, NET | |||||||||||||||
| (Amounts in thousands, except statistical information) | |||||||||||||||
| (Unaudited) | |||||||||||||||
| For the Three Month Period Ended September 30, | For the Nine Month Period Ended September 30, | ||||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||||
| Cash Flows from Operating Activities: | |||||||||||||||
| Net income | $ | 14,661 | $ | 11,501 | $ | 34,389 | $ | 28,659 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||||||
| Depreciation and amortization | 4,185 | 5,214 | 13,139 | 14,662 | |||||||||||
| Provision for doubtful accounts | 7,086 | 5,471 | 18,078 | 13,664 | |||||||||||
| Non-cash compensation | 3,558 | 4,750 | 11,788 | 12,556 | |||||||||||
| 401(k) employer match | 2,180 | 1,694 | 6,547 | 5,134 | |||||||||||
| (Gain) loss on disposal of property and equipment | (169 | ) | 34 | (22 | ) | 556 | |||||||||
| Deferred income taxes | 9,646 | 7,327 | 17,228 | 18,689 | |||||||||||
| Equity in earnings from equity method investments | (900 | ) | (3,244 | ) | (3,149 | ) | (3,602 | ) | |||||||
| Amortization of deferred debt issuance costs | 185 | 185 | 555 | 555 | |||||||||||
| Return on equity investment | 1,240 | 1,551 | 4,656 | 1,913 | |||||||||||
| Changes in operating assets and liabilities, net of impact of acquisitions: | |||||||||||||||
| Patient accounts receivable | (11,099 | ) | (15,758 | ) | (28,924 | ) | (46,107 | ) | |||||||
| Other current assets | 996 | (4,681 | ) | (5,896 | ) | 870 | |||||||||
| Other assets | (11,054 | ) | 34 | (12,202 | ) | (11,909 | ) | ||||||||
| Accounts payable | (6,523 | ) | (1,300 | ) | (5,430 | ) | 7,308 | ||||||||
| Securities Class Action Lawsuit settlement accrual, net | (28,712 | ) | — | — | — | ||||||||||
| Accrued expenses | 25,327 | (6,289 | ) | 22,584 | (9,100 | ) | |||||||||
| Other long-term obligations | (406 | ) | 314 | 201 | (150 | ) | |||||||||
| Net cash provided by operating activities | 10,201 | 6,803 | 73,542 | 33,698 | |||||||||||
| Cash Flows from Investing Activities: | |||||||||||||||
| Proceeds from sale of deferred compensation plan assets | 57 | — | 622 | 230 | |||||||||||
| Purchase of investment | — | (318 | ) | (436 | ) | (750 | ) | ||||||||
| Purchases of property and equipment | (1,625 | ) | (3,587 | ) | (9,074 | ) | (13,502 | ) | |||||||
| Proceeds from sale of property and equipment | 118 | — | 118 | — | |||||||||||
| Acquisitions of businesses, net of cash acquired | — | (3,744 | ) | (24,128 | ) | (31,378 | ) | ||||||||
| Net cash used in investing activities | (1,450 | ) | (7,649 | ) | (32,898 | ) | (45,400 | ) | |||||||
| Cash Flows from Financing Activities: | |||||||||||||||
| Proceeds from issuance of stock upon exercise of stock options and warrants | 11 | — | 4,214 | — | |||||||||||
| Proceeds from issuance of stock to employee stock purchase plan | 611 | 611 | 1,798 | 1,818 | |||||||||||
| Shares withheld upon stock vesting | (728 | ) | — | (6,454 | ) | — | |||||||||
| Tax benefit from stock options exercised and restricted stock vesting | — | 111 | — | 7,241 | |||||||||||
| Non-controlling interest distribution | (126 | ) | (84 | ) | (216 | ) | (284 | ) | |||||||
| Sale of non-controlling interest | — | 405 | — | 405 | |||||||||||
| Proceeds from revolving line of credit | — | 44,500 | — | 128,500 | |||||||||||
| Repayments of revolving line of credit | — | (44,500 | ) | — | (128,500 | ) | |||||||||
| Principal payments of long-term obligations | (1,569 | ) | (1,250 | ) | (4,069 | ) | (3,750 | ) | |||||||
| Purchase of company stock | — | — | — | (12,315 | ) | ||||||||||
| Net cash used in financing activities | (1,801 | ) | (207 | ) | (4,727 | ) | (6,885 | ) | |||||||
| Net increase (decrease) in cash and cash equivalents | 6,950 | (1,053 | ) | 35,917 | (18,587 | ) | |||||||||
| Cash and cash equivalents at beginning of period | 59,164 | 9,968 | 30,197 | 27,502 | |||||||||||
| Cash and cash equivalents at end of period | $ | 66,114 | $ | 8,915 | $ | 66,114 | $ | 8,915 | |||||||
| Supplemental Disclosures of Cash Flow Information: | |||||||||||||||
| Cash paid for interest | $ | 1,016 | $ | 917 | $ | 2,188 | $ | 2,276 | |||||||
| Cash paid for income taxes, net of refunds received | $ | 31 | $ | (67 | ) | $ | 315 | $ | 758 | ||||||
| Days revenue outstanding, net (1) | 40.7 | 40.0 | 40.7 | 40.0 | |||||||||||
(1) Our calculation of days revenue outstanding, net at September 30, 2017 and 2016 is derived by dividing our ending patient accounts receivable (i.e., net of estimated revenue adjustments and allowance for doubtful accounts) by our average daily net patient revenue for the three month periods ended September 30, 2017 and 2016, respectively.
| AMEDISYS, INC. AND SUBSIDIARIES | |||||||
| SEGMENT INFORMATION | |||||||
| (Amounts in millions, except statistical information) | |||||||
| (Unaudited) | |||||||
| Segment Information - Home Health | |||||||
| For the Three Month Period Ended September 30, | |||||||
| 2017 | 2016 | ||||||
| Financial Information (in millions): | |||||||
| Medicare | $ | 191.4 | $ | 203.9 | |||
| Non-Medicare | 78.1 | 65.0 | |||||
| Net service revenue | 269.5 | 268.9 | |||||
| Cost of service | 168.2 | 162.4 | |||||
| Gross margin | 101.3 | 106.5 | |||||
| Other operating expenses | 77.2 | 77.4 | |||||
| Operating income | $ | 24.1 | $ | 29.1 | |||
| Same Store Growth (1): | |||||||
| Medicare revenue | (7 | %) | 1 | % | |||
| Non-Medicare revenue | 19 | % | 4 | % | |||
| Medicare admissions | (3 | %) | 1 | % | |||
| Total Episodic admissions | 1 | % | 3 | % | |||
| Total admissions | 1 | % | — | % | |||
| Key Statistical Data - Total (2): | |||||||
| Medicare: | |||||||
| Admissions | 46,823 | 47,625 | |||||
| Recertifications | 26,996 | 25,522 | |||||
| Total volume | 73,819 | 73,147 | |||||
| Completed episodes | 71,454 | 71,948 | |||||
| Visits | 1,259,156 | 1,266,780 | |||||
| Average revenue per completed episode (3) | $ | 2,820 | $ | 2,841 | |||
| Visits per completed episode (4) | 17.4 | 17.5 | |||||
| Non-Medicare: | |||||||
| Admissions | 26,686 | 24,335 | |||||
| Recertifications | 12,263 | 9,479 | |||||
| Visits | 592,742 | 506,729 | |||||
| Visiting Clinician Cost per Visit | $ | 82.53 | $ | 82.86 | |||
| Clinical Manager Cost per Visit | $ | 8.30 | $ | 8.72 | |||
| Total Cost per Visit | $ | 90.83 | $ | 91.58 | |||
| Visits | 1,851,898 | 1,773,509 | |||||
| For the Nine Month Period Ended September 30, | |||||||
| 2017 | 2016 | ||||||
| Financial Information (in millions): | |||||||
| Medicare | $ | 588.4 | $ | 619.2 | |||
| Non-Medicare | 226.1 | 198.0 | |||||
| Net service revenue | 814.5 | 817.2 | |||||
| Cost of service | 496.1 | 483.6 | |||||
| Gross margin | 318.4 | 333.6 | |||||
| Other operating expenses | 223.0 | 230.5 | |||||
| Operating income | $ | 95.4 | $ | 103.1 | |||
| Same Store Growth (1): | |||||||
| Medicare revenue | (5 | %) | 3 | % | |||
| Non-Medicare revenue | 14 | % | 12 | % | |||
| Medicare admissions | (3 | %) | 3 | % | |||
| Total Episodic admissions | 1 | % | 4 | % | |||
| Total admissions | 1 | % | 3 | % | |||
| Key Statistical Data - Total (2): | |||||||
| Medicare: | |||||||
| Admissions | 143,711 | 147,025 | |||||
| Recertifications | 78,878 | 77,565 | |||||
| Total volume | 222,589 | 224,590 | |||||
| Completed episodes | 217,190 | 218,007 | |||||
| Visits | 3,794,001 | 3,893,568 | |||||
| Average revenue per completed episode (3) | $ | 2,811 | $ | 2,835 | |||
| Visits per completed episode (4) | 17.3 | 17.5 | |||||
| Non-Medicare: | |||||||
| Admissions | 80,244 | 74,139 | |||||
| Recertifications | 33,949 | 28,945 | |||||
| Visits | 1,727,618 | 1,549,760 | |||||
| Visiting Clinician Cost per Visit | $ | 81.41 | $ | 80.52 | |||
| Clinical Manager Cost per Visit | $ | 8.42 | $ | 8.31 | |||
| Total Cost per Visit | $ | 89.83 | $ | 88.83 | |||
| Visits | 5,521,619 | 5,443,328 | |||||
(1) Same store information represents the percent increase (decrease) in our Medicare and Non-Medicare revenue or admissions for the period as a percent of the Medicare and Non-Medicare revenue or admissions of the prior period.
(2) Total includes acquisitions.
(3) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care.
(4) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.
Segment Information - Hospice
| For the Three Month Period Ended September 30, | |||||||
| 2017 | 2016 | ||||||
| Financial Information (in millions): | |||||||
| Medicare | $ | 91.4 | $ | 77.0 | |||
| Non-Medicare | 5.1 | 5.0 | |||||
| Net service revenue | 96.5 | 82.0 | |||||
| Cost of service | 47.8 | 41.9 | |||||
| Gross margin | 48.7 | 40.1 | |||||
| Other operating expenses | 20.4 | 19.3 | |||||
| Operating income | $ | 28.3 | $ | 20.8 | |||
| Same Store Growth (1): | |||||||
| Medicare revenue | 17 | % | 12 | % | |||
| Non-Medicare revenue | (2 | %) | 14 | % | |||
| Hospice admissions | 7 | % | 16 | % | |||
| Average daily census | 14 | % | 14 | % | |||
| Key Statistical Data - Total (2): | |||||||
| Hospice admissions | 6,257 | 5,751 | |||||
| Average daily census | 7,026 | 6,087 | |||||
| Revenue per day, net | $ | 149.25 | $ | 146.49 | |||
| Cost of service per day | $ | 73.99 | $ | 74.77 | |||
| Average discharge length of stay | 95 | 92 | |||||
| For the Nine Month Period Ended September 30, | |||||||
| 2017 | 2016 | ||||||
| Financial Information (in millions): | |||||||
| Medicare | $ | 257.9 | $ | 217.0 | |||
| Non-Medicare | 14.9 | 13.8 | |||||
| Net service revenue | 272.8 | 230.8 | |||||
| Cost of service | 134.9 | 120.1 | |||||
| Gross margin | 137.9 | 110.7 | |||||
| Other operating expenses | 61.7 | 55.6 | |||||
| Operating income | $ | 76.2 | $ | 55.1 | |||
| Same Store Growth (1): | |||||||
| Medicare revenue | 18 | % | 16 | % | |||
| Non-Medicare revenue | 7 | % | 15 | % | |||
| Hospice admissions | 13 | % | 18 | % | |||
| Average daily census | 15 | % | 17 | % | |||
| Key Statistical Data -Total (2): | |||||||
| Hospice admissions | 19,010 | 16,757 | |||||
| Average daily census | 6,705 | 5,776 | |||||
| Revenue per day, net | $ | 149.01 | $ | 145.86 | |||
| Cost of service per day | $ | 73.72 | $ | 75.89 | |||
| Average discharge length of stay | 92 | 94 | |||||
(1) Same store information represents the percent increase (decrease) in our Medicare and Non-Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare and Non-Medicare revenue, Hospice admissions or average daily census of the prior period.
(2) Total includes acquisitions.
Segment Information - Personal Care
| For the Three Month Period Ended September 30, | |||||||
| 2017 | 2016 | ||||||
| Financial Information (in millions): | |||||||
| Medicare | $ | — | $ | — | |||
| Non-Medicare | 14.2 | 10.7 | |||||
| Net service revenue | 14.2 | 10.7 | |||||
| Cost of service | 10.6 | 7.8 | |||||
| Gross margin | 3.6 | 2.9 | |||||
| Other operating expenses | 3.6 | 2.4 | |||||
| Operating income | $ | — | $ | 0.5 | |||
| Key Statistical Data: | |||||||
| Billable hours | 616,036 | 448,133 | |||||
| Clients served | 8,145 | 7,132 | |||||
| Shifts | 281,904 | 203,465 | |||||
| Revenue per hour | $ | 23.00 | $ | 23.70 | |||
| Revenue per shift | $ | 50.26 | $ | 52.19 | |||
| Hours per shift | 2.2 | 2.2 | |||||
| For the Nine Month Period Ended September 30, | |||||||
| 2017 | 2016 | ||||||
| Financial Information (in millions): | |||||||
| Medicare | $ | — | $ | — | |||
| Non-Medicare | 42.1 | 23.2 | |||||
| Net service revenue | 42.1 | 23.2 | |||||
| Cost of service | 31.2 | 16.8 | |||||
| Gross margin | 10.9 | 6.4 | |||||
| Other operating expenses | 10.0 | 5.1 | |||||
| Operating income | $ | 0.9 | $ | 1.3 | |||
| Key Statistical Data: | |||||||
| Billable hours | 1,822,653 | 990,389 | |||||
| Clients served | 11,372 | 8,969 | |||||
| Shifts | 830,151 | 451,421 | |||||
| Revenue per hour | $ | 23.13 | $ | 23.41 | |||
| Revenue per shift | $ | 50.77 | $ | 51.36 | |||
| Hours per shift | 2.2 | 2.2 | |||||
Segment Information - Corporate
| For the Three Month Period Ended September 30, | |||||||
| 2017 | 2016 | ||||||
| Financial Information (in millions): | |||||||
| Other operating expenses | $ | 25.9 | $ | 32.7 | |||
| Depreciation and amortization | 3.1 | 3.3 | |||||
| Total operating expenses | $ | 29.0 | $ | 36.0 | |||
| For the Nine Month Period Ended September 30, | |||||||
| 2017 | 2016 | ||||||
| Financial Information (in millions): | |||||||
| Other operating expenses | $ | 85.4 | $ | 106.4 | |||
| Depreciation and amortization | 9.6 | 9.3 | |||||
| Total operating expenses before Securities Class Action Lawsuit settlement, net | 95.0 | 115.7 | |||||
| Securities Class Action Lawsuit settlement, net | 28.7 | — | |||||
| Total operating expenses | $ | 123.7 | $ | 115.7 | |||
| AMEDISYS, INC. AND SUBSIDIARIES | ||||||||||||||
| RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES | ||||||||||||||
| (Amounts in thousands) | ||||||||||||||
| (Unaudited) | ||||||||||||||
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”): | ||||||||||||||
| For the Three Month Period Ended September 30, | For the Nine Month Period Ended September 30, | |||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||
| Net income attributable to Amedisys, Inc. | $ | 14,558 | $ | 11,435 | $ | 34,149 | $ | 28,344 | ||||||
| Add: | ||||||||||||||
| Income tax expense | 9,364 | 6,693 | 17,324 | 18,323 | ||||||||||
| Interest expense, net | 1,291 | 1,122 | 3,496 | 3,506 | ||||||||||
| Depreciation and amortization | 4,185 | 5,214 | 13,139 | 14,662 | ||||||||||
| Certain items (1) | 7,590 | 1,158 | 37,014 | 14,560 | ||||||||||
| Interest component of certain items (1) | (95 | ) | — | (95 | ) | — | ||||||||
| Adjusted EBITDA (2) (6) | $ | 36,893 | $ | 25,622 | $ | 105,027 | $ | 79,395 | ||||||
| Adjusted Net Service Revenue Reconciliation: | ||||||||||||||
| For the Three Month Period Ended September 30, | For the Nine Month Period Ended September 30, | |||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||
| Net service revenue | $ | 380,163 | $ | 361,595 | $ | 1,129,442 | $ | 1,071,158 | ||||||
| Add: | ||||||||||||||
| Certain items (1) | 6,506 | — | 6,506 | 948 | ||||||||||
| Adjusted net service revenue (3) (6) | $ | 386,669 | $ | 361,595 | $ | 1,135,948 | $ | 1,072,106 | ||||||
| Adjusted Net Income Attributable to Amedisys, Inc. Reconciliation: | ||||||||||||||
| For the Three Month Period Ended September 30, | For the Nine Month Period Ended September 30, | |||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||
| Net income attributable to Amedisys, Inc. | $ | 14,558 | $ | 11,435 | $ | 34,149 | $ | 28,344 | ||||||
| Add: | ||||||||||||||
| Certain items (1) | 4,592 | 700 | 22,394 | 8,809 | ||||||||||
| Adjusted net income attributable to Amedisys, Inc. (4) (6) | $ | 19,150 | $ | 12,135 | $ | 56,543 | $ | 37,153 | ||||||
| Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share: | ||||||||||||||
| For the Three Month Period Ended September 30, | For the Nine Month Period Ended September 30, | |||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||
| Net income attributable to Amedisys, Inc. common stockholders per diluted share | $ | 0.42 | $ | 0.34 | $ | 1.00 | $ | 0.84 | ||||||
| Add: | ||||||||||||||
| Certain items (1) | 0.13 | 0.02 | 0.65 | 0.26 | ||||||||||
| Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (5) (6) | $ | 0.56 | $ | 0.36 | $ | 1.65 | $ | 1.10 | ||||||
(1) The following details the certain items for the three and nine month periods ended September 30, 2017 and 2016:
Certain Items:
| For the Three Month Period Ended September 30, 2017 | For the Nine Month Period Ended September 30, 2017 | |||||||
| (Income) Expense | (Income) Expense | |||||||
| Certain Items Impacting Net Service Revenue: | ||||||||
| Florida ZPIC audit | $ | 6,506 | $ | 6,506 | ||||
| Certain Items Impacting Operating Expenses: | ||||||||
| Acquisition costs | — | 976 | ||||||
| Legal fees - non-routine | 176 | 1,410 | ||||||
| Securities Class Action Lawsuit settlement accrual, net | — | 28,712 | ||||||
| Restructuring activity | 1,670 | 1,670 | ||||||
| Data center relocation | — | 940 | ||||||
| Certain Items Impacting Total Other Income (Expense): | ||||||||
| Legal settlements | (647 | ) | (2,014 | ) | ||||
| Miscellaneous, other (income) expense, net | (115 | ) | (1,186 | ) | ||||
| Total | $ | 7,590 | $ | 37,014 | ||||
| Net of tax | $ | 4,592 | $ | 22,394 | ||||
| Diluted EPS | $ | 0.13 | $ | 0.65 | ||||
| For the Three Month Period Ended September 30, 2016 | For the Nine Month Period Ended September 30, 2016 | ||||||
| (Income) Expense | (Income) Expense | ||||||
| Certain Items Impacting Net Service Revenue: | |||||||
| Third party audit reserve | $ | — | $ | 948 | |||
| Certain Items Impacting Operating Expenses: | |||||||
| HCHB implementation | 1,993 | 7,025 | |||||
| Acquisition costs | 467 | 2,509 | |||||
| Legal fees - non-routine | 374 | 2,350 | |||||
| Restructuring activity | 1,965 | 5,213 | |||||
| Data center relocation | — | 456 | |||||
| Disaster relief | 338 | 338 | |||||
| Certain Items Impacting Total Other Income (Expense): | |||||||
| Legal settlements | (1,242 | ) | (2,048 | ) | |||
| Miscellaneous, other (income) expense, net | (2,737 | ) | (2,231 | ) | |||
| Total | $ | 1,158 | $ | 14,560 | |||
| Net of tax | $ | 700 | $ | 8,809 | |||
| Diluted EPS | $ | 0.02 | $ | 0.26 | |||
(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items as described in footnote 1.
(3) Adjusted net service revenue is defined as net service revenue plus certain items as described in footnote 1.
(4) Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(5) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(6) Adjusted EBITDA, adjusted net service revenue, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measure calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.
